Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Bacterial Lysate In Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children of both genders aged 6 to 16 years.~2. Allergic asthma diagnosis with at least one perennial allergen according to the Global Strategy for Asthma Management and Prevention (GINA 2012 guidelines) prior to screening visit.~3. Patient shows clinical characteristics of partly controlled or uncontrolled asthma according to GINA 2012.~4. Already treated with SABA prn and ICS or ICS + LABA during the previous 3 months.~5. Patient shows antigen-specific IgE against HDM ≥ class 2 or positive skin prick test or RAST for at least one perennial allergen.~6. Patient who had at least 2 exacerbations of asthma within the 12-mo period before V1.~7. Patient not treated with Polyvalent Mechanical Bacterial Lysate (Ismigen®) within the previous 6 months prior to Visit 1.~Exclusion Criteria:~1. Patient received mechanical or any other bacterial lysate immunostimulation within the previous 6 months before Visit 1.~2. Patient received oral/subcutaneous allergen-immunotherapy within the previous 6 months before Visit 1.~3. History of near fatal asthma (e.g. brittle asthma, hospitalization for asthma exacerbation in Intensive Care Unit).~4. Pregnant or breastfeeding woman.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- ISMIGEN (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
- PLACEBO (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest

Based on this trial design, predict the completion outcome and termination type (if applicable).